title: Are ongoing trials on hematologic malignancies still excluding older subjects?
authors.forename: Antonio
authors.initials: A
authors.lastname: Cherubini
authors.forename: Francesca
authors.initials: F
authors.lastname: Pierri
authors.forename: Beatrice
authors.initials: B
authors.lastname: Gasperini
authors.forename: Elisa
authors.initials: E
authors.lastname: Zengarini
authors.forename: Annarita
authors.initials: A
authors.lastname: Cerenzia
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Bonifacio
authors.forename: Flavio
authors.initials: F
authors.lastname: Falcinelli
authors.forename: Fabrizia
authors.initials: F
authors.lastname: Lattanzio
mesh_terms: D000367:Age Factors; D000368:Aged; D019337:Hematologic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000628:therapy; D054437:Myelodysplastic-Myeloproliferative Diseases / Q000175:diagnosis / Q000628:therapy; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000639:trends*; D012042:Registries; D014944:World Health Organization